T cell agonist specialist ImCheck Therapeutics will use €48m (US$53m) from a Series B financing to push clincial pipeline of antibodies activating gamma-delta T-cells.
Pierre Fabre SA and Puma Biotechnology, Inc. have broadened the geographic coverage of their license agreement on commercialisation of Nerlynx® (neratinib).
The European Commission and the European Investment Bank (EIB) have selected ECBF Management GmbH as investment advisor for the €250m EU circular bioeconomy fund.
French researchers have found MALT1 blockers not only to act on blood cancers but also to be effective as a treatment for glioblastoma.
Researchers have designed a limb girdle muscular dystrophy 2A gene therapy preventing cardiotoxicity of calpain3 gene transfer.
Having secured a €2.785m grant from the EU and €4.55m from a Series B round, MaxiVAX is going full steam ahead with its Phase II cancer vaccine programmes.
Geneva-based GeNeuro SA announced a new clinical study of temelimab to treat patients with multiple sclerosis in collaboration with Karolinska Institute and ASC.
Roche AG said on Friday that its PD-L1 blocker Tecentriq plus its VEFG blocker Avastin improved progression-free survival versus sorafinib in a pivotal study in hepatocellular carcinoma (HCC) patients.
Azeria Therapeutics Ltd (Cambridge, UK) has raised a £32m (€37.3m) in a Series B financing led by Syncona Ltd contributing £29.5m (€34.4m).
GHO Capital raises €975m in largest ever European private equity healthcare fund.